CLINICAL ROLE -
American Oncology Network’s Specialty Pharmacy Reports Zero Drug Waste After Value-Based Trial, Secures Unchanged Reimbursement Rate for 2024
AON’s specialty pharmacy reports success in reducing drug waste like unnecessary and early prescription refills.
Expert: The Growth of the 340B Drug Pricing Program Has Influenced the Landscape of Cancer Care
The vice president of pharmacy operations at American Oncology Network discusses the 340B Drug Pricing Program and its growth and impact on community oncology.
American Oncology Network Celebrates Momentous Five-Year Anniversary of Closing the Cancer Care Gap
Since its founding, AON has expanded into 19 states and counting.
American Oncology Network Appoints New Board of Managers Members, Announces Resignation of Two Members
AON celebrates its Board of Managers’ appointments and retirements.
Highlights From SABCS 2022 Clinical Trial Data
Significant study results may help inform clinical practice strategies.
Highlights From the American Society of Hematology Annual Meeting & Exposition
Developments may soon impact clinical practice in hematology and oncology.
American Oncology Network Announces Brad Prechtl’s Retirement After 20 Years of Dedicated Service to Community Oncology
American Oncology Network Ranks No. 107 on the 2022 Inc. 5000 Annual List
AON receives ranking no. 107 among America’s fastest-growing private companies and no. eight among health services.
American Oncology Network Comments Against CMS’ 2023 Outpatient Prospective Payment System
The new proposal will have grave effects on the sustainability of community oncology practices.
American Oncology Network Physicians Research Presented at ASCO22
American Oncology Network and Low Country Cancer Care Expand to Waycross Georgia Opening New Office
American Oncology Network In-House Specialty Pharmacy Earns Third Accreditation
American Oncology Network Names James Gilmore Chief Pharmacy & Procurement Officer
American Oncology Network In-House Specialty Pharmacy Achieves Reaccreditation with ACHC
American Oncology Network, LLC in-house specialty pharmacy is pleased to announce that it has successfully completed reaccreditation through Accreditation Commission for Health Care for specialty pharmacy services.
Optimizing Therapy for Patients With RRMM
Advice for clinical pharmacists who help manage patients with relapsed/refractory multiple myeloma in the current era of novel therapies and recommendations to improve upon current practice patterns.
Clinical Trials of Interest in RRMM
Novel treatment strategies being explored in clinical trials that look exciting in relapsed/refractory multiple myeloma, and implications for using these newer approaches in the future.
RRMM: Educating Pharmacists on Anti-BCMA Therapy
The importance of coordinated care and proper education to pharmacists on best practices when dispensing anti-BMCA therapy to patients with relapsed/refractory multiple myeloma.
RRMM: Adopting Anti-BCMA Therapy into Practice
Robert Mancini, PharmD, BCOP, FHOPA, of St. Luke’s Cancer Institute: Boise, comments on his experience navigating challenges using belantamab mafodotin, an anti-BCMA therapy, to treat relapsed/refractory multiple myeloma.
Belantamab Mafodotin for RRMM
Recommendations for managing patients who receive belantamab mafodotin, an anti-BCMA therapy, for relapsed/refractory multiple myeloma, with special considerations regarding the ocular health of patients.
Novel Agents for Relapsed/Refractory Myeloma
Best practices for prescribing an immunomodulatory-based therapy or a proteasome inhibitor as treatment for relapsed/refractory multiple myeloma.
mAb-based Therapies for Relapsed/Refractory Myeloma
Considerations for treating patients with relapsed/refractory multiple myeloma with elotuzumab, daratumumab, or isatuximab based on more recent clinical trial data and differences between each treatment option.
Backbone Regimens for Relapsed/Refractory Myeloma
Variables considered by healthcare professionals when selecting an appropriate backbone regimen to manage a patient with relapsed or refractory multiple myeloma.
IV Versus Subcutaneous Daratumumab
Healthcare stakeholders comment on current practices managing patients with relapsed/refractory multiple myeloma during the COVID pandemic and discuss their comfort switching patients over from intravenous daratumumab to subcutaneous daratumumab.
Treatment Pathways for Relapsed/Refractory Myeloma
Factors that influence treatment selection for relapsed or refractory multiple myeloma, and suggestions to help streamline decision making and address limitations associated with current treatment pathways.
Relapsed/Refractory Multiple Myeloma: Disease Overview
A historical review of treatment advances in relapsed/refractory multiple myeloma and criteria used to define relapsed or refractory disease.
2 Clarke Drive Cranbury, NJ 08512